428 assets in Triple-Negative Breast Carcinoma

Therapeutic assets addressing Triple-Negative Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rndo-564 Triple-Negative Breast Carcinoma	Rondo Therapeutics	P1	C (39)
sz011 car-nk Triple-Negative Breast Carcinoma	First Affiliated Hospital of Shantou University Medical College	Early P1	C (39)
Technetium Tc 99M Sestamibi Triple-Negative Breast Carcinoma	M.D. Anderson Cancer Center	Early P1	C (39)
TH19P01-DOCETAXEL Triple-Negative Breast Carcinoma	Theratechnologies	P1	C (39)
Vidutolimod Triple-Negative Breast Carcinoma	Regeneron Pharmaceuticals	P2	C (39)
xb010 Triple-Negative Breast Carcinoma	Exelixis	P1	C (39)
Zymosan Triple-Negative Breast Carcinoma	George T. Budd	Early P1	C (39)
Α-Lactalbumin Vaccine Triple-Negative Breast Carcinoma	George T. Budd	Early P1	C (39)
Ruxolitinib Triple-Negative Breast Carcinoma	Baylor Research Institute	Early P1	C (38)
177lu-dfc413 Triple-Negative Breast Carcinoma	Novartis Pharmaceuticals	P1	C (37)
[177lu]lu-nns309 Triple-Negative Breast Carcinoma	Novartis Pharmaceuticals	P1	C (37)
[68Ga]Ga-NNS309 Triple-Negative Breast Carcinoma	Novartis Pharmaceuticals	P1	C (37)
68Ga-NNS309 Triple-Negative Breast Carcinoma	Novartis Pharmaceuticals	P1	C (37)
Abbv-400 Triple-Negative Breast Carcinoma	AbbVie	P1	C (37)
ag-01 compound Triple-Negative Breast Carcinoma	A&G Pharmaceutical Inc.	P1	C (37)
Alpha-Type-1 Polarized Dendritic Cells Triple-Negative Breast Carcinoma	Roswell Park Cancer Institute	P2	C (37)
Amt-151 Triple-Negative Breast Carcinoma	Multitude Therapeutics Inc.	P1	C (37)
Anti-Ny-Eso-1 Tcr Transduced T Cells Triple-Negative Breast Carcinoma	University of Southern California	P1	C (37)
Astx 660 Triple-Negative Breast Carcinoma	Institute of Cancer Research, United Kingdom	P1	C (37)
Atv-1601 Triple-Negative Breast Carcinoma	Atavistik Bio, Inc	P1	C (37)
Atx-295 Triple-Negative Breast Carcinoma	Accent Therapeutics	P1	C (37)
Azirkitug Triple-Negative Breast Carcinoma	AbbVie	P1	C (37)
Bdc-3042 Triple-Negative Breast Carcinoma	Bolt Biotherapeutics, Inc.	P1	C (37)
Biological Ni-1801 Triple-Negative Breast Carcinoma	Light Chain Bioscience - Novimmune SA	P1	C (37)
Budigalimab Triple-Negative Breast Carcinoma	AbbVie	P1	C (37)
Bulumtatug Fuvedotin Triple-Negative Breast Carcinoma	Mabwell (Shanghai) Bioscience Co., Ltd.	P1	C (37)
CD47/SIRPA-BLOCKING AGENT ALX148 Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P1	C (37)
Cid-078 Monotherapy Triple-Negative Breast Carcinoma	Circle Pharma	P1	C (37)
CRX100 Triple-Negative Breast Carcinoma	BioEclipse Therapeutics	P1	C (37)
Ctx-8371 Triple-Negative Breast Carcinoma	Compass Therapeutics	P1	C (37)
Daratumumab Triple-Negative Breast Carcinoma	Andrew Hantel, MD	P1	C (37)
dky709 Triple-Negative Breast Carcinoma	Novartis Pharmaceuticals	P1	C (37)
dr-0202 Triple-Negative Breast Carcinoma	Dren Bio	P1	C (37)
Fam-Trastuzumab Deruxtecan-Nxki Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P1	C (37)
Gcar1 Triple-Negative Breast Carcinoma	Canadian Cancer Trials Group	P1	C (37)
her2 - primed dendritic cells Triple-Negative Breast Carcinoma	H. Lee Moffitt Cancer Center and Research Institute	P1	C (37)
her3 - primed dendritic cells Triple-Negative Breast Carcinoma	H. Lee Moffitt Cancer Center and Research Institute	P1	C (37)
hh160 Triple-Negative Breast Carcinoma	Huahui Health	P1	C (37)
Humanized Immunoglobulin G1-Kappa Anti-(Human Cd8) Fused At The C-Terminus Of One Heavy Chain, Via Peptide Linker <Sup>449</Sup> Sggggsggggsggggs<Sup>464</Sup>, To A Variant Of Human Interleukin-2, Glycoform Alfa Triple-Negative Breast Carcinoma	Washington University School of Medicine	P1	C (37)
ic9-car.b7-h3 t cell therapy Triple-Negative Breast Carcinoma	UNC Lineberger Comprehensive Cancer Center	P1	C (37)
ide034 Triple-Negative Breast Carcinoma	IDEAYA Biosciences	P1	C (37)
Itc-6146Ro Triple-Negative Breast Carcinoma	IntoCell, Inc	P1	C (37)
Itraconazole Triple-Negative Breast Carcinoma	Eli Lilly and Company	P1	C (37)
ly4052031 Triple-Negative Breast Carcinoma	Eli Lilly and Company	P1	C (37)
ly4101174 Triple-Negative Breast Carcinoma	Eli Lilly and Company	P1	C (37)
ly4175408 Triple-Negative Breast Carcinoma	Eli Lilly and Company	P1	C (37)
lyl797 Triple-Negative Breast Carcinoma	Lyell Immunopharma, Inc.	P1	C (37)
Mem-288 Intratumoral Triple-Negative Breast Carcinoma	Memgen, Inc.	P1	C (37)
Naptumomab Estafenatox Triple-Negative Breast Carcinoma	NeoTX Therapeutics Ltd.	P1	C (37)
Navitoclax Triple-Negative Breast Carcinoma	Sunnybrook Health Sciences Centre	P1	C (37)

Showing 351 to 400 of 428 assets

PreviousPage 8 of 9Next